Nuclear Medicine Communications最新文献

Purpose: This study aimed to investigate the differential patterns of anterior abdominal wall (AAW) radiotracer accumulation using pretherapeutic technetium-99m macroaggregated albumin ( 99m Tc-MAA) single photon emission computed tomography/computed tomography (SPECT/CT) and posttherapeutic yttrium-90 ( 90 Y) positron emission tomography/CT (PET/CT) imaging in 90 Y resin microspheres selective internal radiation therapy (SIRT).

Materials and methods: A retrospective analysis was conducted on 204 patients with unresectable liver malignancies who underwent SIRT between August 2022 and November 2024. Pretherapeutic evaluation included diagnostic angiography and 99m Tc-MAA imaging. Posttherapeutic 90 Y-PET/CT was performed within 24 h of treatment to verify microspheres distribution. Patients with AAW accumulation on 99m Tc-MAA images or 90 Y-microspheres PET/CT images were analyzed, and follow-up results for at least 3 months served as reference standards.

Results: Among 204 patients, 21 (10.3%) showed AAW accumulation on 99m Tc-MAA images or 90 Y-microspheres PET/CT images. Concordant findings between 99m Tc-MAA images and 90 Y-PET/CT images were observed in 11(11/21, 52.4%) cases, while five cases (5/21, 23.8%) showed accumulation only on 90 Y-PET/CT images, and the other five cases (5/21, 23.8%) showed accumulation only on 99m Tc-MAA images. The hepatic falciform artery (HFA) was found in two patients. Mild abdominal pain was observed in four patients, and only one patient experienced abdominal dermatitis, which resolved spontaneously. The remaining patients did not experience any relevant side effects during the follow-up period.

Conclusion: AAW-related complications were infrequent and mild, suggesting that a patent HFA may not be considered a contraindication for SIRT; however, discordance between 99m Tc-MAA and 90 Y-PET/CT highlights the need for vigilant posttreatment monitoring, even in cases without pretherapeutic AAW accumulation.

Aim: This study aimed to evaluate the accuracy of the 6-month evaluation to accept treatment failure after a single dose of radioactive iodine (RAI) for Graves' disease and to decide whether to repeat the dose.

Methods: This study retrospectively analyzed 104 patients who received a single dose of RAI between 2003 and 2022, had regular follow-up for at least 2 years, and did not have extrathyroidal symptoms. The study group was divided into two groups: patients who developed hypothyroidism within the first 6 months and patients who developed hypothyroidism after 6 months, and statistically analyzed.

Results: The mean administered dose of RAI was 10.6 ± 4.4 mCi, and the average duration of hypothyroidism was 5.5 ± 5.4 months. In patients with late-onset hypothyroidism (>6 months), the 2-h iodine uptake values were significantly higher, and post-RAI thyroid-stimulating hormone levels were significantly lower. While 58.5% of patients with early-onset hypothyroidism (<6 months) required antithyroid drug (ATD) therapy after RAI, all patients who developed hypothyroidism after 6 months received supportive ATD treatment. The 24-h iodine uptake values were significantly higher in the hypothyroid group compared with the euthyroid group. During follow-up, 26.9% of patients were hypothyroid at 0-3 months, 62.5% at 3-6 months, and 77.9% at 12 months. While 20.2% of patients remained hyperthyroid at 6 months, this rate declined to 3.8% at 12 months.

Conclusion: This study suggests that the 6 th month following RAI treatment in patients with Graves' disease may not be sufficient to assess treatment response, as hypothyroidism tends to develop cumulatively over time. Iodine uptake values at 2 and 24 h may serve as useful indicators for predicting the development of early or late hypothyroidism, while also helping to guide the maintenance of a euthyroid state.

Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disorder that frequently presents as fever of unknown origin (FUO), posing a diagnostic challenge. This study aimed to systematically review the diagnostic utility of 18 F-labeled fluorodeoxyglucose ( 18 F-FDG) PET/computed tomography (CT) in AOSD. A systematic review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered in PROSPERO (CRD42023443831). Databases searched included PubMed, EMBASE, and Ovid up to December 2022. We included case reports, case series, cross-sectional, case-control, cohort studies, and clinical trials reporting PET/CT findings in adult patients diagnosed with AOSD. Data extraction included demographics, PET/CT findings, tracers used, standardized uptake values (SUVs), and diagnostic criteria applied. Data were analyzed following the SWiM framework because of heterogeneity. From 155 records, 54 studies (545 patients) were included. The majority were case reports or series ( n  = 40), with 14 observational studies or trials. 18 F-FDG was used in 85% of cases, predominantly for diagnostic purposes (77.7%). The most commonly used diagnostic criteria were Yamaguchi (63%). The highest maximum SUV (SUV max ) values were observed in the bone marrow (4.0 ± 1.4), spleen (4.0 ± 1.9), and liver (4.2 ± 2.1). PET/CT findings frequently revealed diffuse hypermetabolism in these organs, aiding in distinguishing AOSD from infectious or malignant etiologies. 18 F-FDG PET/CT appears to be a useful adjunct in the diagnostic workup of AOSD, especially in cases presenting as FUO. Typical uptake patterns in bone marrow, spleen, liver, and lymph nodes may support the diagnosis, though biopsy remains essential to exclude neoplastic mimics.

Rationale: Staging primary prostate cancer with prostate specific membrane antigen (PSMA) PET/computed tomography is incorporated in recent guidelines, given its pivotal role in guiding therapy selection and prognostication. Little is known about differences in diagnostic performance between different PSMA tracers. In this study the performance of 18F-DCFPyL (PyL) is compared with 18F-PSMA-JK7 (JK7) in primary staging.

Methods: Interpatient comparison of 250 patients scanned with PyL and 250 with JK7. Detection of primary lesions and metastases in locoregional lymph nodes, distant lymph nodes, bone, and other distant metastases as well as clinical outcomes in an operated subcohort were compared. Differences were reported as odds ratios (ORs) and were calculated by means of an univariable and multivariable logistic regression.

Results: No significant differences in detection of metastases between PyL and JK7 were found; locoregional lymph nodes (OR: 0.81, P = 0.34), distant lymph nodes (OR: 1.15, P = 0.60), bone (OR: 0.91, P = 0.72) and other distant metastases (OR: 0.95, P = 0.91). In a subcohort of 68 operated patients the true-negative rate was 86 and 90% and the false-negative rate was 14 and 10% for PyL and JK7 (P = 0.52), respectively.

Conclusion: No clinically relevant differences are found between PyL and JK7 for staging of primary prostate cancer. Both in terms of detection rates of primary tumor and metastases as well as in terms of PET true-negative and false-negative rates in the subcohort treated with surgery. This data indicates that the diagnostic value of JK7 is comparable to PyL.

Background: Hepatocellular carcinoma (HCC) is a highly prevalent malignant tumor worldwide, with Chinese patients accounting for more than 50%. Microvascular invasion (MVI) is a significant risk factor for postoperative recurrence of HCC. 18 F-fluorodeoxyglucose PET/computed tomography ( 18 F-FDG PET/CT), as a hybrid imaging modality integrating metabolic information from PET with anatomical details from CT. This combined approach enables simultaneous assessment of glucose metabolism and structural features. It can also evaluate tumor biological behavior through metabolic parameters and heterogeneity characteristics.

Objective: To explore the predictive value of 18 F-FDG PET/CT metabolic parameters and heterogeneity index for MVI in HCC patients before liver transplantation and to construct a nomogram prediction model.

Methods: A retrospective study involving 177 HCC patients who underwent liver transplantation (100 MVI-positive cases and 77 MVI-negative cases) was conducted to analyze the correlation between clinical characteristics, PET/CT metabolic parameters (SUVmax, SUVmean, TLG, and TLR), and heterogeneity parameters (COV and HI) with MVI. Independent predictors were identified using univariate and multivariate logistic regression, and a nomogram model was constructed. The model's performance was evaluated using calibration curves and ROC curves.

Results: Univariate analysis showed significant differences in PIVKA-II, SUVmax, TLG, TLR, COV, and HI between the two groups (all P  < 0.05). Multivariate analysis indicated that PIVKA-II (OR = 1.000, P = 0.042), TLG (OR = 0.999, P = 0.024), HI (OR = 1.022, P < 0.001), and TLR (OR = 1.618, P = 0.031) were independent predictors of MVI. The area under the ROC curve (AUC) of the combined model reached 0.815 (95% confidence interval: 0.754-0.876), significantly better than any single parameter. The nomogram calibration curve showed a high consistency between predicted probabilities and actual observed probabilities (mean absolute error = 0.025).

Conclusion: The integration of PET/CT-derived parameters-specifically TLG (metabolic burden), HI (heterogeneity), and TLR (tumor-to-liver contrast)-with serum PIVKA-II provides a robust tool for preoperative MVI prediction in HCC patients undergoing liver transplantation. The validated nomogram model (AUC = 0.815) outperforms individual parameters, offering a reliable basis for clinical decision-making.

Purpose: This study aimed to evaluate correlation between various parameters from integrated 82-rubidium PET/coronary computed tomography angiography (RbPET/CCTA), like coronary artery calcium (CAC) score, coronary artery disease-reporting and data system (CAD-RADS), myocardial ischemia scores, and myocardial blood flow parameters [stress myocardial blood flow (sMBF) and myocardial flow reserve (MFR)].

Methods: In this retrospective study, 184 consecutive patients [107 women, 77 men, median age: 67 years [(interquartile range: 61-74 years)] with suspicion of CAD were imaged with RbPET/CCTA in the 'one-stop imaging' approach. The association between CAC score, CAD-RADS, relative perfusion, and myocardial blood flow was assessed.

Results: There was a weak but statistically significant inverse correlation between the global CAD-RADS score and global sMBF ( ρ = -0.239, P = 0.001) and global MFR ( ρ = -0.248, P = 0.0001). There was a significant difference in CAD-RADS 3-5 vs. CAD-RADS 0-2 for global as well as per-vessel sMBF and MFR values ( P < 0.05). There was a very weak inverse correlation between global CAC and global sMBF ( ρ = -0.165, P = 0.026) and a nonsignificant, very weak inverse correlation between global CAC and global MFR ( ρ = -0.120, P = 0.106).

Conclusion: Combined CCTA and RbPET 'one-stop imaging' provides comprehensive anatomical and physiological information in patients with suspected CAD. The PET and computed totmography parameters seem to lack linear and robust correlation. In the given circumstances, CAD-RADS scores appear to have a relatively better, though weak, correlation with sMBF, MFR, and relative ischemia scores compared with CAC scores.

Objective: Relative to planar imaging, macro-aggregated albumin-single photon emission tomography/computed tomography (MAA-SPECT/CT) offers more reliable lung shunt fraction (LSF) and lung mean dose (LMD) estimates in 90 Y radioembolization. But lung truncation in SPECT/CT can limit its utility, yielding uncertain LSF and LMD estimates. Here, the effects of lung mass on LSF and LMD corrections for lung truncation in SPECT/CT were analyzed.

Methods: 106 cases with planar LSF > 8% were analyzed. Lung truncation was simulated in 30 cases with full lung coverage, while 50 cases with clinical truncation were also assessed. Five LMD estimates were computed: (1) planar-imaging, 1-kg lung-mass (Planar 1-kg ), (2) planar-imaging, patient-specific lung-mass (Planar), (3) uncorrected-truncated SPECT and lung-mass (SPECT Trunc ), (4) truncation-corrected SPECT, 1-kg lung-mass (SPECT 1-kg ), (5) truncation-corrected SPECT, patient-specific lung-mass (SPECT Fit ). Bland-Altman analysis (mean difference ± 95% prediction interval; PI = 1.96σ) was used to compare the LMD estimates.

Results: Planar 1-kg and Planar LMD were comparable on average, but variability was high (mean ± 95% PI: 0.1 ± 7.8 Gy). The mean ± 95% PI in LMD for Planar 1-kg relative to nontruncated-SPECT (SPECT True ) was 10.4 ± 11.4 Gy. LMD differences relative to SPECT True were 0.3 ± 1.0 Gy for SPECT Trunc , 0.1 ± 1.0 Gy for SPECT 1-kg , and 0.1 ± 1.1 Gy for SPECT Fit . In clinically truncated cases, differences between Planar 1-kg and SPECT Trunc were again high (11.2 ± 10.3 Gy), with differences between SPECT Trunc , SPECT 1-kg , and SPECT Fit much smaller (mean <0.2 Gy, 95% PI < 2.0 Gy).

Conclusion: The most impactful difference in estimating LMD is using SPECT/CT data in place of planar imaging. Even when lung mass is unknown or a reference value (1-kg) is used, truncated MAA-SPECT/CT offers more robust LMD estimates than planar imaging.

Introduction: Accurate lymph node staging is essential for treatment planning and prognosis in non-small cell lung cancer (NSCLC). [ 18 F]Fluorodeoxyglucose Positron emission tomography/computed tomography ([ 18 F]FDG PET/CT) is a widely used non-invasive imaging modality. Lymph node size and maximum standardized uptake value (SUVmax) are the most utilized parameters but with known limitations. We hypothesized the lymph node-to-primary tumor SUVmax ratio (N/T SUV ratio) could mitigate the limitations and provide a more reliable diagnostic measure.

Objective: This study aims to evaluate the diagnostic accuracy of the N/T SUV ratio in comparison to other PET/CT parameters.

Materials and methods: This retrospective study evaluated consecutive patients with [ 18 F]FDG PET/CT done in Tuen Mun Hospital, Hong Kong between January 2023 and December 2023. PET/CT parameters, including SUVmax, N/T SUV ratio, visual score, and lymph node size, were analyzed. Receiver operating characteristic curves were used to determine optimal diagnostic cutoffs. Subgroup analyses were conducted based on lymph node and primary tumor characteristics.

Results: A total of 62 patients with 98 histologically confirmed lymph nodes were included. N/T SUV ratio (cutoff: 0.5) demonstrated the highest diagnostic accuracy (area under curves: 0.924), with a sensitivity of 82.69% and specificity of 95.65%. It remained consistent across patient subgroups and outperformed SUVmax, visual score, and lymph node size in distinguishing metastatic from benign nodes.

Conclusion: N/T SUV ratio (cutoff: 0.5) demonstrates the best consistency and robustness across patient subgroups, mitigating SUVmax variability. Its simplicity and reproducibility make it a valuable parameter for NSCLC nodal staging. Further studies with larger, multicenter prospective cohorts are warranted to validate its application.